Today, the clinical-stage gene therapy company, announced its recent strategic agreement with GSK, to acquire its portfolio of approved and investigational rare disease gene therapies.
The spinout from the UCL Institute of Child Health, is dedicated to transforming the lives of patients with rare diseases through gene therapy. The recent acquisition strengthens the company’s position as a global leader in this area.
In the agreement, GSK also becomes an investor in Orchard Therapeutics, receiving an equity stake of 19.9% and a seat on the company’s board.
Read more about the recent agreement here.